Publications by authors named "T Kushibiki"
Durvalumab plus platinum-based chemotherapy is the first-line treatment for extensive-stage small-cell lung cancer. Immune checkpoint inhibitors (durvalumab) can cause immune-related adverse events (irAEs). We herein report the first case of fatal sepsis with anti-interleukin-6 autoantibody production following durvalumab administration.
View Article and Find Full Text PDFBackground: The effectiveness of negative-pressure wound therapy (NPWT) in skin graft fixation has been demonstrated in several clinical studies. However, in vitro and in vivo studies on skin graft fixation with NPWT have been scarce. In this in vivo study, we aimed to determine whether NPWT fixation enhances skin graft survival and how it contributes to improving skin graft survival biologically.
View Article and Find Full Text PDFArticle Synopsis
- Negative-pressure wound therapy (NPWT) is a method that enhances wound healing by creating a vacuum over the wound area, which has been used for 25 years in various medical situations.
- Although NPWT has shown promise, there is a lack of molecular biological evidence due to delays in research, highlighting the need for more in-depth studies.
- The focus of research is shifting from just understanding NPWT's main actions to examining its broader effects on different cells, bacteria, and surgical wounds, aiming to strengthen the scientific foundation for its clinical applications.
Background: Although the clinical efficacy of negative-pressure wound therapy (NPWT) is well known, many of its molecular biological mechanisms remain unresolved, mainly due to the difficulty and paucity of relevant in vitro studies. We attempted to develop an in vitro cell culture system capable of real-time monitoring of cells during NPWT treatment.
Materials And Methods: A novel negative-pressure cell culture system was developed by combining an inverted microscope, a stage-top incubator, a sealed metal chamber for cell culture, and an NPWT treatment device.